

FIRST INTERNATIONAL CONFERENCE OF **ANTICANCER RESEARCH**

October 26-30, 1985 Loutraki, Greece

Editorial Office: 5 Argyropoulou Street
Kato Patissia
Athens GR-111 45
Greece

Dr. Alfredo Millá Santos
Instituto Policlinico
Platón 21
Barcelona 6

SPAIN

Dear Colleague:

I am pleased to inform you that your paper has been accepted for presentation at the 1st Int'l Conference of Anticancer Research.

The abstract of your paper will be included in the Book of Abstracts of the Conference as well as in *Anticancer Research* Volume 5, No.6, 1985.

Your presentation has also been selected to be invited for submission as a full paper or as an extended abstract for publication in the volume of *Anticancer Research* comprising the Conference Proceedings. Your paper should comply with the Instructions to Authors of our journal and should be submitted not later than January 31, 1986 to the Editorial Office.

I wish to assure you that we will do our utmost to make your stay in Greece scientifically fruitful, pleasant and unforgettable.

I look forward to welcoming you at beautiful Loutraki in October.

Yours sincerely,



John G. Delinassios
Managing Editor



FUNDACIÓ
RUBIÓ

FIRST INTERNATIONAL CONFERENCE OF **ANTICANCER RESEARCH**

October 26-30, 1985 Loutraki, Greece

ABSTRACT REPRODUCTION FORM

Fill out exactly according to example

Topic Number 2

I prefer to present my paper as

1. ☒ Oral presentation of ☐ 10; ☒ 15; ☐ 20 minutes.
2. ☐ Poster presentation.
3. ☐ at the organizers discretion.

MEDULLARY RECUPERATION BY AM3 IN BREAST CANCER PATIENTS SUBMITTED TO AGGRESSIVE ADJUVANT THERAPY. A PRELIMINARY REPORT.

A. Milla*, F. Sanchiz*, G. Sada**, V.G. Villarrubia**

*Servicio de Terapéutica Física y Oncología Médica. Instituto Policlínico. Barcelona. Spain

**Departamento Médico-Científico. Laboratorios Andrómaco, S.A. Madrid. Spain

One of the most important problems which oncologists have to confront is myelodepression caused by cytostatic agents. This impaired haematological situation is frequently responsible of alterations in the protocolized therapeutic schedules in cancer. In a first attempt to restore these haematopoietic disorders we have studied the activity of a new drug, AM3*, in a prospective randomized clinical trial in breast cancer. 26 out of 46 mastectomized patients with ductal breast carcinoma, (T₂A - T₂B; T₃A; N₁B; M₀) with more than 3 positive axillary nodes, were treated with AM3 associated to local (56 Gy) and regional (50 Gy) radiotherapy plus chemotherapy (CMF, Bonadonna's criteria. 1976). The incidence of medullary hypoplasia was 26,9 % against a 65 % in the control group. Moreover none of the AM3 treated patients developed thrombocytopenia and the nadir of peripheral blood leukocytes was remarkably increased as it is shown in the table:

TREATMENT	MYELODEPRESSION Nº of cases	LEUKOPENIA nadir	THROMBOCYTOPEN. Nº of cases
CFM + RADIOTHER. (n=20)	13/20 (65,0 %)	1.900 leu/ml	11/20 (55 %)
CFM + RADIOTHER. + AM3 (n=26)	7/26** (26,9 %)	4.000 leu/ml	0/26

**(χ^2) $P < 0.05$

*AM3 is a new biological response modifier fully active by oral route and chemically defined as a polysaccharide of fungal origin non covalently bound to a peptidic fraction.



FUNDACIÓ
RUBIÓ